---
title: "Claseprubart (DNTH103) in Generalized myasthenia gravis: Prevalence"
description: "Formulary evidence on Claseprubart (DNTH103) in Generalized myasthenia gravis: Prevalence. Topics: United States, 2021 claims and electronic health records: diagnosed prevalence of all myasthenia gravis; United States, 2017 claims and 2021 extrapolation: prevalence and number of adults with all myasthenia gravis; United States, Medicare fee-for-service beneficiaries aged 65 years and older: prevalence of all myasthenia gravis, 2006 to 2019; Global meta-analysis of 63 studies: prevalence of all myasthenia gravis; 4 further topics. 8 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description/prevalence"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-15T22:20:57-05:00"
---

# Claseprubart (DNTH103) in Generalized myasthenia gravis: Prevalence

<a id="heading-2.2.1.2.2"></a>

## 2.2.1.2.2 Prevalence of Generalized myasthenia gravis

<a id="topic-2.2.1.2.2-1"></a>

### United States, 2021 claims and electronic health records: diagnosed prevalence of all myasthenia gravis

> “The diagnosed prevalence and incidence of MG in the United States in 2021 were calculated to be 37.0 per 100,000 persons and 3.1 per 100,000 persons, respectively.”
> “The updated prevalence and incidence of MG in the United States in 2021 are higher than previous reports from the 1980s and early 2000s, following a global trend of increased prevalence and incidence for this disorder in the last few decades.”

Source: [Rodrigues et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38040629/)

<a id="topic-2.2.1.2.2-2"></a>

### United States, 2017 claims and 2021 extrapolation: prevalence and number of adults with all myasthenia gravis

> “Using a previously validated algorithm, we identified cases of MG in two Truven Health MarketScan databases, which during 2017 included a sample of approximately 20 million commercially insured and Medicare recipients, plus 10 million Medicaid recipients.”
> “From the US commercially/Medicare-insured cohort, we calculated an age-and sex-standardized incidence of 68.5 new cases per million person-years with an adjusted prevalence of 316.4 per million.”
> “Within the Medicaid-insured population, similar yet slightly lower numbers emerged: the adjusted incidence was 49.7 new cases per million person-years, and the adjusted prevalence rate was 203.7 cases per million.”
> “Given our results, we were able to estimate that there were approximately 82,715 US adults living with MG in 2021 (or an estimated 320.2 cases per million adults in the USA).”

Source: [Ye et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10907989/)

<a id="topic-2.2.1.2.2-3"></a>

### United States, Medicare fee-for-service beneficiaries aged 65 years and older: prevalence of all myasthenia gravis, 2006 to 2019

> “The period prevalence of MG increased from 81 to 119 per 100,000 FFS A/B population from 2006–2007 to 2018–2019 (p < 0.001).”
> “Increasing trends of prevalence were observed in all sex (male/female), age (65–69/70–74/75–79/80+), race/ethnic (African American/Asian/Hispanics of any race/non-Hispanic White/other), and census region (Northeast/Midwest/South/West) subgroups.”

Source: [Bruckman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11540456/)

<a id="topic-2.2.1.2.2-4"></a>

### Global meta-analysis of 63 studies: prevalence of all myasthenia gravis

> “After deleting articles unrelated to the research question, finally, 63 articles with a sample size of 1,206,961,907 people were included in the meta-analysis.”
> “The prevalence of MG worldwide was estimated to be 12.4 people (95% CI 10.6–14.5) per 100,000 population.”
> “which has the highest prevalence in the Americas with 19 people (95% CI 15–23.8)”

Source: [Salari et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8686543/)

<a id="topic-2.2.1.2.2-5"></a>

### Global systematic review of studies through February 2024: prevalence of all myasthenia gravis

> “Prevalence of MG ranged from 20 to 475 cases per million, with a mean prevalence of 173.3 (95% confidence interval [CI]: 129.7–215.5) cases per million and a median prevalence of 129.6 cases per million.”
> “The mean PR was 97.5 (95% CI: 59.9–141.9; range: 20–174.2) cases per million considering studies from 1952 to 2007 (the most recent period investigated by the last systematic review [7]), while the mean PR increased up to 220.1 (95% CI: 149.3–288.1; range: 78–475) cases per million considering the period 2008–2021.”
> “North America showed a mean PR of 341.4 (range: 142–475) cases per million”
> “Most of the included studies (81.9%) examined all types of MG (ALL MG), reporting prevalence (59 studies), incidence (50 studies), and mortality (16 studies).”

Source: [Sciancalepore et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12500283/)

<a id="topic-2.2.1.2.2-6"></a>

### Global systematic review of studies from 1950 to 2007: pooled prevalence of all myasthenia gravis

> “The observed PR ranged from 15 to 179 per million”
> “The estimated pooled PR is 77.7 cases per million (C.I.: 63.98, 94.30) but, as for IR there was marked heterogeneity with I2 = 98% (C.I.: 97-98%) observed across studies limiting interpretation.”

Source: [Carr et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2905354/)

<a id="topic-2.2.1.2.2-7"></a>

### Taiwan, 2009 to 2019: prevalence of generalized myasthenia gravis

> “The number of patients with gMG increased from 1,576 in 2009 to 2,638 in 2019 and the mean (standard deviation) age from 51.63 (17.32) to 55.38 (16.29) years.”
> “The prevalence of patients with gMG increased annually from 6.83/100,000 population in 2009 to 11.18/100,000 population in 2019 (p < 0.0001).”
> “The total number of patients with MG (ocular or generalized) increased from 3,647 in 2009 to 6,293 in 2019, with prevalence rates that increased annually from 15.80 per 100,000 population to 26.67 per 100,000 population, a 1.7-fold increase over the study period”

Source: [Herr et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10327564/)

<a id="topic-2.2.1.2.2-8"></a>

### Canada, Ontario, 2013 to 2020: prevalence of all myasthenia gravis

> “MG prevalence increased from 36 to 42 per 100,000 over the study period.”

Source: [Barnett-Tapia et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13498700/)

## Related pages
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references.md)
